MCID: PLY011
MIFTS: 63

Polycystic Ovary Syndrome

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Polycystic Ovary Syndrome

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 38 12 25 37 55 43 44 15 73
Polycystic Ovarian Syndrome 76 53 25
Polycystic Ovaries 12 29 55
Pcos 12 53 25
Polycystic Ovarian Disease 12 25
Stein-Leventhal Syndrome 12 25
Sclerocystic Ovaries 25 73
Multicystic Ovaries 12 25
Polycystic Ovary Syndrome, Susceptibility to 6
Sclerocystic Ovarian Degeneration 25
Sclerocystic Ovary Syndrome 25
Cystic Disease of Ovaries 25
Cystic Disease of Ovary 25
Stein-Leventhal Synd. 12
Polycystic Ovary 12
Pcod 25
Pco 25

Classifications:



External Ids:

Disease Ontology 12 DOID:11612
ICD10 33 E28.2
ICD9CM 35 256.4
MeSH 44 D011085
NCIt 50 C26862
KEGG 37 H01739

Summaries for Polycystic Ovary Syndrome

MedlinePlus : 43 Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include Irregular menstrual periods Infertility Pelvic pain Excess hair growth on the face, chest, stomach, or thighs Weight gain Acne or oily skin Patches of thickened skin Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. PCOS is more common in women who have obesity, or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF). NIH: National Institute of Child Health and Human Development

MalaCards based summary : Polycystic Ovary Syndrome, also known as polycystic ovarian syndrome, is related to aromatase deficiency and glucose intolerance, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is ENSG00000234940 (
It may contribute to the occurrence of PCOS and affect oocyte development.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Glucose / Energy Metabolism and HIF-1 signaling pathway. The drugs Metformin and Cyproterone Acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and skin, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

NIH Rare Diseases : 53 Polycystic ovarian syndrome (PCOS) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. Women with this condition typically have high levels of  hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. The cause of PCOS is unknown, but probably involves a combination of genetic and environmental factors. Treatment for PCOS may involve birth control pills and medications for diabetes and infertility. Medicines called anti-androgens are also used to speed the growth of hair and clear acne.

Genetics Home Reference : 25 Polycystic ovary syndrome is a condition that affects women in their child-bearing years and alters the levels of multiple hormones, resulting in problems affecting many body systems.

Disease Ontology : 12 A syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

Wikipedia : 76 Polycystic ovary syndrome (PCOS) is a set of symptoms due to elevated androgens (male hormones) in... more...

Related Diseases for Polycystic Ovary Syndrome

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 202, show less)
# Related Disease Score Top Affiliating Genes
1 aromatase deficiency 33.1 CYP19A1 GNRH1 INS
2 glucose intolerance 31.6 IGF1 INS INSR SHBG
3 gestational diabetes 31.4 CAPN10 INS INSR SHBG
4 amenorrhea 31.4 GNRH1 PRL SHBG
5 hyperinsulinism 31.3 IGF1 INS INSR SHBG
6 ovarian disease 31.2 CYP11A1 CYP19A1 GDF9 GNRH1 IGF1 INS
7 insulin-like growth factor i 31.1 IGF1 INS INSR PRL SHBG
8 acanthosis nigricans 31.1 IGF1 INS INSR PRL SHBG
9 androgenic alopecia 31.0 CYP19A1 PRL SHBG
10 hyperprolactinemia 31.0 GNRH1 IGF1 PRL SHBG
11 breast disease 30.9 IGF1 PRL SHBG
12 anovulation 30.8 CYP19A1 GNRH1 IGF1 INS PRL SHBG
13 precocious puberty 30.8 CYP19A1 CYP21A2 GNRH1
14 central precocious puberty 30.7 GNRH1 IGF1
15 acromegaly 30.6 IGF1 INS PRL
16 transsexualism 30.6 CYP17A1 CYP19A1 CYP21A2
17 diabetes mellitus, noninsulin-dependent 30.5 CAPN10 GAS5 IGF1 INS INSR SHBG
18 hyperglycemia 30.4 IGF1 INS INSR
19 diabetes mellitus 30.2 CAPN10 IGF1 INS INSR SHBG
20 premature ovarian failure 1 30.2 CYP11A1 CYP19A1 GDF9 GNRH1 PRL SHBG
21 lipoid congenital adrenal hyperplasia 30.1 CYP11A1 CYP17A1 CYP19A1 CYP21A2
22 hyperandrogenism 29.9 CYP17A1 CYP19A1 CYP21A2 GNRH1 IGF1 INS
23 estrogen excess 29.8 CYP19A1 SHBG
24 endometrial cancer 28.9 CYP19A1 GAS5 GNRH1 IGF1 INS SHBG
25 polycystic ovary syndrome 1 12.3
26 cortisone reductase deficiency 11.3
27 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 11.3
28 hair-an syndrome 11.2
29 insulin autoimmune syndrome 11.0 INS INSR
30 acth-independent macronodular adrenal hyperplasia 11.0
31 ovarian cyst 11.0
32 secondary adrenal insufficiency 10.9 IGF1 INS
33 galactorrhea 10.9 IGF1 PRL
34 oocyte maturation defect 1 10.9 CYP19A1 FST
35 hypoactive sexual desire disorder 10.9 CYP19A1 SHBG
36 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.8 IGF1 INS INSR
37 sheehan syndrome 10.8 IGF1 INS PRL
38 hyperpituitarism 10.8 IGF1 INS PRL
39 donohue syndrome 10.8 IGF1 INS INSR
40 androgen insensitivity, partial 10.8 CYP19A1 SHBG
41 pseudohypoparathyroidism, type ia 10.8 IGF1 PRL
42 fetal macrosomia 10.8 IGF1 INS INSR
43 pituitary apoplexy 10.8 GNRH1 INS PRL
44 endometriosis of uterus 10.8 GNRH1 PRL
45 thyroid gland disease 10.8 IGF1 INS PRL
46 hypogonadotropism 10.7 GNRH1 PRL
47 overnutrition 10.7 IGF1 INS SHBG
48 hyperthyroidism 10.7 INS PRL SHBG
49 gynecomastia 10.7 CYP19A1 PRL SHBG
50 cell type benign neoplasm 10.7 IGF1 INS PRL
51 chromophobe adenoma 10.7 GNRH1 INS PRL
52 premenstrual tension 10.7 GNRH1 PRL SHBG
53 pituitary infarct 10.7 GNRH1 IGF1 PRL
54 hypothalamic disease 10.7 GNRH1 PRL
55 empty sella syndrome 10.7 GNRH1 IGF1 PRL
56 chiasmal syndrome 10.7 GNRH1 PRL
57 varicocele 10.7 GNRH1 PRL SHBG
58 mccune-albright syndrome 10.7 CYP19A1 IGF1 PRL
59 acquired metabolic disease 10.6 IGF1 INS PRL SHBG
60 pituitary adenoma 1, multiple types 10.6 IGF1 PRL
61 infertility 10.6
62 alopecia, androgenetic, 1 10.6 CYP19A1 CYP21A2 SHBG
63 cryptorchidism, unilateral or bilateral 10.6 CYP19A1 GNRH1 SHBG
64 gonadal disease 10.6 GNRH1 IGF1 INS SHBG
65 cytochrome p450 oxidoreductase deficiency 10.6 CYP17A1 CYP21A2
66 pituitary gland disease 10.5 GNRH1 IGF1 INS PRL
67 craniopharyngioma 10.5 GNRH1 IGF1 INS PRL
68 stuttering 10.5 CYP17A1 CYP19A1 GNRH1
69 hypopituitarism 10.5 GNRH1 IGF1 INS PRL
70 acute adrenal insufficiency 10.5 CYP11A1 CYP21A2
71 endotheliitis 10.5
72 luteoma 10.5 CYP19A1 CYP21A2
73 body mass index quantitative trait locus 1 10.5
74 aging 10.5
75 mammographic density 10.5 CYP17A1 CYP19A1 IGF1 PRL
76 antley-bixler syndrome 10.4 CYP17A1 CYP19A1 CYP21A2
77 male reproductive organ cancer 10.4 CYP17A1 GNRH1 IGF1 SHBG
78 penis agenesis 10.4 CYP17A1 GNRH1
79 pituitary-dependent cushing's disease 10.4 CYP21A2 GNRH1 INS PRL
80 testicular leydig cell tumor 10.3 CYP11A1 CYP17A1 CYP21A2
81 thyroiditis 10.3
82 steroid inherited metabolic disorder 10.3 CYP11A1 CYP17A1 CYP21A2
83 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 10.3 CYP11A1 CYP17A1 CYP21A2
84 fatty liver disease 10.3
85 adrenal cortical adenoma 10.3 CYP11A1 CYP17A1 CYP21A2
86 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 10.3 CYP11A1 CYP17A1 CYP21A2
87 liver disease 10.3
88 nonalcoholic fatty liver disease 10.3
89 depression 10.3
90 adrenal adenoma 10.3 CYP11A1 CYP17A1 CYP21A2
91 adrenal carcinoma 10.2 CYP11A1 CYP17A1 CYP21A2
92 hypothyroidism 10.2
93 ovarian hyperstimulation syndrome 10.2
94 reproductive system disease 10.1 CYP19A1 GDF9 GNRH1 INS PRL SHBG
95 hepatitis 10.1
96 leydig cell tumor 10.1 CYP11A1 CYP17A1 CYP19A1 CYP21A2
97 anxiety 10.1
98 placenta disease 10.1
99 autonomic dysfunction 10.1
100 adrenocortical carcinoma, hereditary 10.1 CYP11A1 CYP17A1 CYP19A1 CYP21A2
101 fatty liver disease, nonalcoholic 1 10.0
102 conn's syndrome 10.0 CYP11A1 CYP17A1 CYP21A2
103 sleep apnea 10.0
104 borderline personality disorder 10.0
105 prostatitis 10.0
106 personality disorder 10.0
107 pancreatitis 10.0
108 intracranial hypertension 10.0
109 nonalcoholic steatohepatitis 10.0
110 body mass index quantitative trait locus 11 9.9 CAPN10 CYP21A2 IGF1 INS INSR SHBG
111 apnea, obstructive sleep 9.9
112 arteries, anomalies of 9.9
113 hepatic adenomas, familial 9.9
114 transsexuality 9.9
115 coronary heart disease 1 9.9
116 alopecia 9.9
117 coronary artery anomaly 9.9
118 hepatocellular adenoma 9.9
119 partial lipodystrophy 9.9
120 heart disease 9.9
121 goiter 9.9
122 graves' disease 9.9
123 nodular goiter 9.9
124 vascular disease 9.9
125 cervicitis 9.9
126 endometriosis 9.9
127 gingivitis 9.9
128 adenoma 9.9
129 idiopathic central precocious puberty 9.9
130 female reproductive system disease 9.8 CYP17A1 CYP19A1 GDF9 GNRH1 INS PRL
131 cherubism 9.7
132 osteoporosis 9.7
133 peutz-jeghers syndrome 9.7
134 thrombophilia due to thrombin defect 9.7
135 wilms tumor 1 9.7
136 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 9.7
137 hemochromatosis, type 1 9.7
138 intracranial hypertension, idiopathic 9.7
139 androgen insensitivity syndrome 9.7
140 major affective disorder 2 9.7
141 helicobacter pylori infection 9.7
142 wilms tumor 5 9.7
143 acute insulin response 9.7
144 homocysteinemia 9.7
145 major affective disorder 4 9.7
146 major affective disorder 5 9.7
147 major affective disorder 6 9.7
148 major affective disorder 8 9.7
149 major affective disorder 7 9.7
150 major affective disorder 9 9.7
151 myelodysplastic syndrome 9.7
152 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
153 wilms tumor 6 9.7
154 bipolar disorder 9.7
155 morbid obesity 9.7
156 familial partial lipodystrophy 9.7
157 ectopic pregnancy 9.7
158 thrombosis 9.7
159 mucositis 9.7
160 endometrial disease 9.7
161 pre-eclampsia 9.7
162 chlamydia 9.7
163 vogt-koyanagi-harada disease 9.7
164 eclampsia 9.7
165 generalized anxiety disorder 9.7
166 papilledema 9.7
167 hereditary angioedema 9.7
168 angioedema 9.7
169 epilepsy 9.7
170 vaginitis 9.7
171 thrombocytosis 9.7
172 hidradenitis suppurativa 9.7
173 hidradenitis 9.7
174 thrombophilia 9.7
175 cystadenoma 9.7
176 myoma 9.7
177 endometrial adenocarcinoma 9.7
178 carbohydrate metabolic disorder 9.7
179 adenocarcinoma 9.7
180 lipid metabolism disorder 9.7
181 teratoma 9.7
182 mood disorder 9.7
183 periodontal disease 9.7
184 retinitis 9.7
185 sleep disorder 9.7
186 conjunctivitis 9.7
187 periodontitis 9.7
188 peritonitis 9.7
189 eating disorder 9.7
190 psoriasis 9.7
191 hypoglycemia 9.7
192 mitochondrial disorders 9.7
193 3-beta-hydroxysteroid dehydrogenase deficiency 9.7
194 mosaic variegated aneuploidy syndrome 9.7
195 non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 9.7
196 tetraploidy 9.7
197 trisomy 12 mosaicism 9.7
198 headache 9.7
199 mosaic trisomy 12 9.7
200 refractory anemia 9.7
201 sex differentiation disease 9.6 CYP17A1 CYP19A1 CYP21A2 GNRH1 INS PRL
202 prostate cancer 8.2 CYP17A1 CYP19A1 GAS5 GNRH1 IGF1 MSR1

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome

Symptoms & Phenotypes for Polycystic Ovary Syndrome

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

46 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 GNRH1 CAPN10 IGF1 CYP11A1 INS CYP17A1
2 endocrine/exocrine gland MP:0005379 10.02 CAPN10 IGF1 CYP11A1 INS INSR CYP19A1
3 adipose tissue MP:0005375 9.85 CAPN10 IGF1 INS CYP17A1 INSR CYP19A1
4 liver/biliary system MP:0005370 9.7 CAPN10 CYP11A1 INS INSR CYP19A1 PRL
5 renal/urinary system MP:0005367 9.5 CAPN10 IGF1 INS CYP17A1 INSR CYP19A1
6 reproductive system MP:0005389 9.32 IGF1 CYP11A1 INS CYP17A1 INSR CYP19A1

Drugs & Therapeutics for Polycystic Ovary Syndrome

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 344, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
2
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 427-51-0
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
4 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
5
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
6
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
7
Orlistat Approved, Investigational Phase 4,Phase 2,Not Applicable 96829-58-2 3034010
8
Ganirelix Approved Phase 4,Early Phase 1 123246-29-7, 124904-93-4 25081094
9
Drospirenone Approved Phase 4,Phase 3,Phase 1,Not Applicable 67392-87-4 68873
10
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-23-7 5754
11
Pioglitazone Approved, Investigational Phase 4,Not Applicable,Early Phase 1 111025-46-8 4829
12
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
13
Menotropins Approved Phase 4,Phase 2,Phase 1,Not Applicable 61489-71-2, 9002-68-0 5360545
14
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
15
Zinc Approved, Investigational Phase 4,Early Phase 1,Not Applicable 7440-66-6 23994
16
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
17
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 1,Not Applicable 501-36-0 445154
18
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
19
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 71-58-9
20
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
21
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 616-91-1 12035
22
Liraglutide Approved Phase 4 204656-20-2 44147092
23
Citalopram Approved Phase 4 59729-33-8 2771
24
Epinephrine Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 51-43-4 5816
25
Racepinephrine Approved Phase 4,Not Applicable,Early Phase 1 329-65-7 838
26
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999
27
Leuprolide Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 53714-56-0 3911 657181
28
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
29
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
30
Alogliptin Approved Phase 4 850649-61-5 11450633
31
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
32
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
33
Tamoxifen Approved Phase 4 10540-29-1 2733526
34
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
35
Desogestrel Approved Phase 4,Phase 3 54024-22-5 40973
36
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
37
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
38
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 77-92-9 311
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 143 6006
41
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
43
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 67-97-0 6221 5280795
44
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 73-31-4 896
45
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
46
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
47
Cyanocobalamin Approved, Nutraceutical Phase 4,Not Applicable 68-19-9 44176380
48
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
49
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Not Applicable 13422-55-4
50
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
51
Enclomiphene Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15690-57-0
52 Deslorelin Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57773-65-6
53
2,4-thiazolidinedione Investigational Phase 4,Early Phase 1 2295-31-0
54 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
55 Androgen Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
56 Androgens Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
57 Contraceptive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
58 Contraceptive Agents, Male Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
59
Cyproterone Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 2098-66-0 5284537
60 Cyproterone acetate, ethinyl estradiol drug combination Phase 4,Phase 2,Not Applicable
61 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
62 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
63 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
64 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
65 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
66 Antidepressive Agents Phase 4
67 Anti-Obesity Agents Phase 4,Phase 3,Phase 2,Not Applicable
68 Appetite Depressants Phase 4,Phase 3
69 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
70 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
71 Psychotropic Drugs Phase 4
72 Clomiphene Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
73 Zuclomiphene Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
74 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
75 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
76 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
77 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
78 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
79 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
80 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
81 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
82 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
83 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
84 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
85 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
86 Contraceptives, Oral Phase 4,Phase 2,Phase 3,Not Applicable
87 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
88 Luteolytic Agents Phase 4,Phase 3,Not Applicable
89 Triptorelin Pamoate Phase 4,Phase 3,Not Applicable
90 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
91 Contraceptives, Oral, Combined Phase 4,Phase 2,Phase 3,Not Applicable
92 diuretics Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
93 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
94 Drospirenone and ethinyl estradiol combination Phase 4,Phase 3,Phase 1,Not Applicable
95 Hemostatics Phase 4,Phase 2
96 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
97 Mineralocorticoids Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
98 Natriuretic Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
99 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
100 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
101 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
102 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
103 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Not Applicable
104 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Not Applicable
105 Liver Extracts Phase 4,Phase 2,Phase 3,Not Applicable
106 Hematinics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
107 Incretins Phase 4,Phase 3,Phase 2,Not Applicable
108 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
109 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
110 Cortisol succinate Phase 4,Not Applicable,Early Phase 1
111 Hydrocortisone 17-butyrate 21-propionate Phase 4,Not Applicable,Early Phase 1
112 Hydrocortisone acetate Phase 4,Not Applicable,Early Phase 1
113 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Not Applicable
114 Autonomic Agents Phase 4,Phase 3,Not Applicable,Early Phase 1
115 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
116 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
117 Anticholesteremic Agents Phase 4,Phase 3,Phase 2,Not Applicable
118 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
119 Progestins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
120 Central Nervous System Depressants Phase 4,Not Applicable
121 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
122 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
123 Analgesics Phase 4,Phase 2,Phase 1,Not Applicable
124 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Not Applicable
125 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
126 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 1,Not Applicable
127 Antineoplastic Agents, Phytogenic Phase 4,Not Applicable
128 Antirheumatic Agents Phase 4,Phase 2,Phase 1,Not Applicable
129 Platelet Aggregation Inhibitors Phase 4,Not Applicable
130 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
131 Antiemetics Phase 4,Phase 3,Not Applicable,Early Phase 1
132 Thioctic Acid Phase 4,Phase 1,Not Applicable
133
Medroxyprogesterone Phase 4,Phase 3,Phase 1,Not Applicable 520-85-4 10631
134 Antihypertensive Agents Phase 4,Not Applicable
135 Antidotes Phase 4,Phase 2,Phase 3,Not Applicable
136 Antiviral Agents Phase 4,Phase 2,Phase 3,Not Applicable
137 Expectorants Phase 4,Phase 2,Phase 3,Not Applicable
138 N-monoacetylcystine Phase 4,Phase 2,Phase 3,Not Applicable
139 Respiratory System Agents Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
140 Nicotinic Acids Phase 4
141 Vasodilator Agents Phase 4,Not Applicable
142 Glucagon-Like Peptide 1 Phase 4,Phase 3,Not Applicable
143 Mitogens Phase 4,Early Phase 1
144 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
145 Antidepressive Agents, Second-Generation Phase 4
146 Cholinergic Agents Phase 4
147 Cholinergic Antagonists Phase 4
148 Epinephryl borate Phase 4,Not Applicable,Early Phase 1
149 Muscarinic Antagonists Phase 4
150 Neurotransmitter Uptake Inhibitors Phase 4
151 Parasympatholytics Phase 4
152 Serotonin Agents Phase 4
153 Serotonin Uptake Inhibitors Phase 4
154 Phosphodiesterase 4 Inhibitors Phase 4
155 Phosphodiesterase Inhibitors Phase 4
156 Follicle Stimulating Hormone Phase 4,Phase 3,Not Applicable,Early Phase 1
157 Dipeptidyl-Peptidase IV Inhibitors Phase 4,Phase 3
158 HIV Protease Inhibitors Phase 4,Phase 3,Not Applicable,Early Phase 1
159
protease inhibitors Phase 4,Phase 3,Not Applicable,Early Phase 1
160 Sitagliptin Phosphate Phase 4
161 Phytoestrogens Phase 4
162 Vitamin B 12 Phase 4,Not Applicable
163 Dermatologic Agents Phase 4,Not Applicable
164 Cardiac Glycosides Phase 4,Not Applicable
165 Glycoside Hydrolase Inhibitors Phase 4,Not Applicable
166 glucocorticoids Phase 4,Phase 3,Not Applicable,Early Phase 1
167 Dacuronium Phase 4
168 Tin Fluorides Phase 4
169 glucagon Phase 4,Phase 3,Not Applicable
170 Methylprednisolone acetate Phase 4
171 Methylprednisolone Hemisuccinate Phase 4
172 Neuroprotective Agents Phase 4,Phase 3
173 Prednisolone acetate Phase 4
174 Prednisolone hemisuccinate Phase 4
175 Prednisolone phosphate Phase 4
176 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
177 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
178 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
179 carnitine Nutraceutical Phase 4
180 Calciferol Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
181 Vitamin D2 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
182 Alpha-lipoic Acid Nutraceutical Phase 4,Phase 1,Not Applicable
183 cysteine Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable
184 Vitamin B3 Nutraceutical Phase 4
185 Olive Nutraceutical Phase 4,Not Applicable
186
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
187
Cobalamin Nutraceutical Phase 4,Not Applicable 13408-78-1 6438156
188 Vitamin B12 Nutraceutical Phase 4,Not Applicable
189 Acidophilus Nutraceutical Phase 4
190 Bifidobacterium Nutraceutical Phase 4
191
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
192
Dopamine Approved Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
193
Cetrorelix Approved, Investigational Phase 3,Phase 2,Not Applicable 120287-85-6 16129715 25074887
194
Chromium Approved Phase 3 7440-47-3 27668
195
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Not Applicable,Early Phase 1 50-02-2 5743
196
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
197
Saxagliptin Approved Phase 3 361442-04-8 11243969
198
Benzocaine Approved, Investigational Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
199
Empagliflozin Approved Phase 2, Phase 3 864070-44-0
200
Phentermine Approved, Illicit Phase 3 122-09-8 4771
201
Topiramate Approved Phase 3 97240-79-4 5284627